Skip to content

Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health

TIMET 2.0 - Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07189234
Acronym
TIMET 2
Enrollment
140
Registered
2025-09-23
Start date
2025-10-23
Completion date
2029-01-06
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Pre-diabetes

Keywords

Time Restricted Eating, Fasting

Brief summary

In a randomized controlled trial, the investigators intend to measure the health impact of time restricted eating (TRE) in patients with metabolic syndrome (with elevated blood pressure and at least 2 of the following: increased waist circumference, abnormal cholesterol levels, elevated triglycerides, and elevated fasting glucose levels), who habitually eat more than 12 hours every day. Patients will be randomly assigned to a control group (standard of care) or intervention group (TRE).

Detailed description

Circadian rhythms optimize nutrient homeostasis by orchestrating catabolic and anabolic metabolism to appropriate times of the 24 hour day. Chronic circadian rhythm disruption predisposes individuals to metabolic diseases including obesity and type 2 diabetes. Conversely, maintaining a daily rhythm of feeding and fasting cycles sustains a robust circadian rhythm which improves cellular bioenergetics and results in improved metabolism. Time-restricted eating (TRE) is a specific feeding-fasting pattern in which feeding is restricted to 8-12 hours a day. Over the 54-week duration of the study, participants will be required to use a smartphone application (myCircadianClock, developed by the Salk Institute) to log all food and beverage intake. Investigators will measure height, weight, waist circumference, and blood pressure throughout the study. Blood tests will be done after an overnight fast to check HbA1C, glucose, insulin, lipids, and an NMR lipoprotein profile. Blood sugar will also be monitored continuously using a continuous glucose monitor (CGM) worn for 2 weeks at the beginning of the study, at 6 months, and at 12 months (end of the study). At these same three timepoints, participants will also wear a wrist-worn actigraphy device (actiwatch) to track physical activity and sleep patterns. Body composition will be measured using a dual energy X-ray absorptiometry (DEXA) scan, and an oral glucose tolerance test (OGTT) will be performed to assess how the body responds to sugar.

Interventions

BEHAVIORALTime-restricted eating (TRE) + Standard of Care

Participants in this arm will adhere to a daily, consistent 10-hour eating window for the course of the study as well as receive nutritional counseling from the study dietician.

BEHAVIORALStandard of Care

Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt the 10-hour eating window.

Sponsors

University of California, San Diego
Lead SponsorOTHER
Salk Institute for Biological Studies
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18-75 years 2. HbA1c: 5.7% to 7.0% 3. Metabolic syndrome (must meet 3 criteria): 1. Elevated systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg OR an antihypertensive therapy) 2. Elevated waist circumference: \- In Asians: ≥ 90 cm in men, ≥80 cm in women In all other races: ≥ 102 cm in men, ≥ 88 cm in women 3. Fasting plasma triglycerides ≥ 150 mg/dL, or on drug treatment for elevated triglycerides d) Reduced High-density lipoprotein (HDL)- cholesterol \< 40 mg/dL in males or \< 50 mg//dL in females, or drug treatment for reduced HDL-cholesterol e) Fasting glucose ≥ 100 mg/dL 4. Own a smartphone (Apple iOS or Android OS) 5. Baseline eating period ≥12 hour/day 6. Patients on a stable dose of cardiovascular medications (HMG CoA reductase inhibitors \[statins\]), other lipid-modifying drugs (including over-the-counter drugs such as red yeast rice and fish oil), or anti-hypertensive drugs) for at least 1 month are allowed. 7. Patients on GLP-1 R agonists, SGLT2 inhibitors, or Metformin must be on stable doses for at least 3 months.

Exclusion criteria

1. Use of sulfonylurea or insulin. 2. HbA1C \> 7.0% 3. Pregnant or breastfeeding. Anyone of reproductive age will receive pregnancy test prior to DXA scan. 4. Caregiver for a dependent requiring frequent nocturnal care / sleep interruptions. 5. Shift workers with variable (e.g. nocturnal) hours. 6. Frequent travel to different time zones during the study period. 7. Active tobacco use or illicit drug use or history of treatment for alcohol abuse. 8. History of major adverse cardiovascular event within the past year (acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack). 9. History of surgical intervention for weight management within the past 2 years, or longer if deemed unsafe following review by medical investigators 10. Uncontrolled arrhythmia (i.e. rate -controlled atrial fibrillation / atrial flutter are not

Design outcomes

Primary

MeasureTime frameDescription
Change in Glucose Levels54 weeksAssessed via HbA1c (%)

Secondary

MeasureTime frameDescription
Change in glycemic variability54 weeksMeasured by continuous glucose monitor (CGM)
Change in direct LDL-C54 weeksLDL cholesterol (mg/dl)
Change in bone density54 weeksBone density measured by DEXA scan (g/cm\^2)
Change in insulin sensitivity54 weeksMeasured by oral glucose tolerance test (OGTT)
Changes in muscle mass54 weeksMuscle mass measured by DEXA scan (kg)
Change in body fat54 weeksMeasured by body fat percentage via DEXA scan (%)

Countries

United States

Contacts

CONTACTGavin McLaren
preventivecvresearch@health.ucsd.edu(858) 246-2342
PRINCIPAL_INVESTIGATORPam Taub, MD

UC San Diego Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026